Company announcements · 11/15/20261 min read

IDEAYA Biosciences Annuntiat Nominationem Candidati Ad Progressum IDE101, Inhibitor Potentialis Prima Classe CDKN2A-Deficientia in Tumoribus Solidis

Local automatic translation · Lingua originalis fontis

Illustration generated by Business News; it is not a source photograph.

Summary

Candidatus ad progressum ostendit activitatem promittentem in modelis tumoribus CDKN2A-deficientibus solum et cum inhibitoribus RAS et MTAP, includens inhibitorum PRMT5 IDEAYA proprium IDE892 in Phase 1. CDKN2A-deficientia est defectus communis in supressorem tumoris.

Lingua originalis fontis: PR Newswire — Global News ReleasesOpen original release →

Related companies

WITH
Open profile →Explore businesses on Business Maps →